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Recent advances in systems-oriented approaches and 'omics technologies have led to an assortment of new computational tools that promise to enable a more informed and successful implementation of the drug discovery workflow than the reductionist "one drug for one target for one disease" approach (Westerhoff and Palsson, 2004). Computational tools for the analysis of biological data can help decipher the mechanism or mechanisms that underlie a disease state or the mechanism of action of a drug by offering a holistic view of the system. These tools enable identification of promising pathways for modulation and selection of potential inhibitors (Fotis et al., 2018). In this review, we focus on the recent discovery of neuroheal (NH) through a systems biology approach and the use of artificial intelligence-based tools. NH is neuroprotective and pro-regenerative and pre-clinical data indicate that it holds promise as a co-adjuvant treatment to facilitate recovery of nervous system function after traumatic injury to the peripheral nerves.

There is a medical need for function recovery after a disruption of the neuron-target connection resulting from trauma-associated peripheral nerve injury (PNI) due to traffic, laboral or sportive accidents. These injuries usually occur at working ages and its consequences range from mild discomfort to life-long impairment accompanied of paralysis, sensory disturbances, anaesthesia, lack of autonomic functions in the affected body areas and neuropathic pain. PNI has a prevalence of 1.3--2.8% (Noble et al., 1998; Taylor et al., 2008; Castillo-Galván et al., 2014) and surgical repair is the best therapeutical option depending on the PNI degree. This, together with sick leave spending time, increases substantially the economic and social burden being the estimated annual cost in USA health care range from of USD 5.13 Billion in 2016 and the compound annual growth rate of 12.3% (<https://www.marketsandmarkets.com>). The prognosis and functional recovery after PNI depends on the severity of the injury, the gap distance between disrupted nerve stumps, the length of the nerve to be regenerated and the extend of target reconnection. Moreover, axonal integrity disruption or axonal retraction may be provoked by non-traumatic disorders such as peripheral neuropathies acquired during lifetime such as those induced by diabetes mellitus, antineoplastic agents or infiltrating tumours, or those relates with genetical disorders such as Charcot-Marie-tooth or amyotrophic lateral sclerosis disease (England and Asbury, 2004; Taylor et al., 2011; Laing, 2012; Robberecht and Philips, 2013; Ale et al., 2014).

Injuries affecting the nerve roots, close to the interface between central and peripheral nervous systems, are the most devastating types of PNI. Nerve roots can be transected or separated by mechanical traction, which is commonly termed root avulsion (RA). RA is often caused by high-energy traffic accidents (mainly motor vehicle) or sport-related incidents (*e.g.*, American football), by iatrogenic injuries, and during obstetric interventions (Pondaag et al., 2004; Buitenhuis et al., 2012; Daly et al., 2016; Kachramanoglou et al., 2017). RA can affect single roots or nerve plexus from brachial, lumbar, and facial zones (Htut et al., 2007). Adult brachial plexus injury is present in 1.2% of the multi-trauma admission patients in Canada, and 450--500 supraclavicular injuries with root affectation occur every year in UK (Goldie and Coates, 1992). Neonatal brachial plexus injury affects 2 or 3 of 1000 births (Pondaag et al., 2004). Currently, the only treatment for brachial plexus injury is surgical nerve root reimplantation. The timing for surgical repairing is critical mainly due to the progressive motoneuronal soma (MN) death triggered after injury (Htut et al., 2007).

Complete motor functional recovery after PNI, and particularly after RA, requires five main steps: i) sustained survival of axotomized MNs; ii) promotion of axonal regrowth across the glial scar formed at the ventral-root intermediate zone; iii) axonal elongation through the degenerated distal nerve stump to the target muscle; iv) establishment of functional connections to denervated muscle, and v) prevention of muscle atrophy. Whether or not these steps occur depends on factors such as the patient's age, the type of lesion, the distance from the injury to the target organ, and the timing and type of surgical repair (Navarro et al., 2007). We have performed a PubMed literature search of articles published with the search term "neuroheal", "nerve root avulsion", and "peripheral nerve injury".

Experimental Models to Study Peripheral Nerve Lesions {#sec1-2}
=====================================================

Successful discovery of drugs that can be used as adjuvants to surgical intervention after PNI requires first the existence of good models. *In vivo* models are widely used to mimic the PNI and have been used to identify factors that modulate axonal regeneration and MN death. MN survival depends on the severity and type of the injury, the distance from the neuronal soma, and the age of the animals. Rat spinal MNs are extremely susceptible to the transection of the nerve by avulsion from the spinal cord affecting the roots and is defined as preganglionic (proximal to the dorsal root ganglia). Usually affecting roots from brachial or lumbosacral plexus (Penas et al., 2009). But adult MNs are resistant to postganglionic transection (Vanden Noven et al., 1993; Valero-Cabre et al., 2004) with the exception of immature MNs still in development (Snider et al., 1992; Lowrie et al., 1994; Sun and Oppenheim, 2003). There are also differences among organisms since, for instance, cranial hypoglossal MNs are susceptible to the transection of the hypoglossal nerve at distal level in mice but not in rats (Kiryu-Seo et al., 2005). Models based on nerve crush produced by compression that lead to the axonal continuity breakdown (axonotmesis) allow a reasonably good recovery, whereas those in which neurotmesis is produced by complete transection of the nerve leads to a poor functional recovery of the animals, although the latter model better recapitulates the clinical features of PNI (Lago and Navarro, 2006).

The rational design of neuroprotective agents is often based on knowledge of the underlying mechanisms of neurodegeneration. In this regard, it is important to determine which process of cell death affects disconnected MNs. After axotomy, a neuronal retrograde response is initiated whose intensity and time course is influenced by maturational stage and MN subset as well as by the site and type of axonal injury and the age and species of animal. In neonates, axotomized MNs undergo apoptosis as a result of the lack of muscle-derived trophic supports (Snider et al., 1992). The aggressiveness of the process after RA is characterized by a drastic reduction of MN survival, which results in death of around 80% of MNs by 4 weeks post injury (Penas et al., 2009). Models obtained either through sciatic root or facial nerve avulsion result in similar losses of MNs but with some mechanistic differences (Watabe et al., 2005).

We have recently shed light on the mechanisms of MN death after RA in adult rats using unbiased comparative proteomic analysis combined with a systems biology approach for data mining (Casas et al., 2015). Our study showed that several programs, such as apoptosis and anti-apoptosis pathways, run in parallel and counterbalance to result in an overall non-apoptotic degenerative process (Li et al., 1998; Penas et al., 2011a) and anoikis. In contrast, when nerve avulsion is milder, not performed at the root but distally, the process may shift towards an apoptotic process, which upon sciatic nerve avulsion leads rapid loss of about 50% of MNs by two weeks post injury ((Martin et al., 1999, 2005) and personal observations). These observations reveal that to be clinically effective a neuroprotective agent should be plastic enough to protect against both forms of neuronal death.

Although these models of RA allow study of the mechanisms of degeneration and target discovery, more sophisticated models have been also characterized that better mimic clinical issues after surgical repair. Some authors have performed RA of ventral or brachial roots combined with an immediate reparative surgery (Eggers et al., 2010; Pintér et al., 2010; Torres-Espín et al., 2013). However, immediate repair cannot be carried out clinically because, among other reasons, patients need to be stabilized after the accident. Gu et al. (2005) were the first to evaluate delayed repair of the avulsed roots, and recently we set up a new *in vivo* rat model that combines RA of L3--6 ventral roots with delayed surgical repair (Romeo-Guitart et al., 2017). This model can be used to test new therapies against MN degeneration in the context of post-injury axonal regrowth. Importantly, this model reproduces long-term denervated muscle atrophy, which is essential for functional recovery (Romeo-Guitart et al., 2017).

Network-Centric Discovery of a New Neuroprotective Agent: Neuroheal {#sec1-3}
===================================================================

Many observations indicate the existence of multiple endogenous mechanisms of neuroprotection. Endogenous defence of the nervous system is a continuous process that simultaneously performs and integrates the neurobiological processes of tropism, neuroprotection, neuroplasticity, and neurogenesis. Clinical activation of endogenous protective strategies dates back more than six decades when Noble and collaborators observed that short periods of global hypoxia can protect the entire mammalian organism and preserve brain energy metabolism when re-exposed to longer periods of hypoxia (Noble, 1943). These early studies were the foundation for subsequent intensive research on the mechanisms involved in this type of protective pre-conditioning. However, drug discovery efforts have focused on identification of agents that suppress pathobiological processes rather than on discovery of drugs that enhance intrinsic neuroprotective pathways. This reductionist vision has not led to many successful therapies for neurodegeneration.

To identify a neuroprotective agent capable of boosting the endogenous mechanisms normally triggered after trauma, we took advantage of the existence of solid molecular knowledge on the mechanisms triggered after trauma and computational tools for handling and extracting meaning from biological data. We realized that dissimilar reactions occur in MNs after proximal and distal axotomy that lead to opposite readouts: MN degeneration vs. MN survival, respectively. We wondered which mechanisms triggered by distally axotomized MNs allowed them to recover from damage and even regenerate. We envisaged that mimicking these endogenous mechanisms might be neuroprotective for proximal axotomized degenerating MNs as well. In support of this hypothesis, we observed that although similar molecular mechanisms were initially triggered by both distal and proximal RA axotomy, there are differences in extent of neurodegeneration at seven days post injury (Penas et al., 2011a; Casas et al., 2015). Hence, we had identified the precise time to investigate and dissect out pro-survival mechanisms from pro-degenerative ones. We used proteomics and a systems biology approach to perform unbiased analysis of both models. We discovered that MN degeneration after RA was characterized by concurrent programs such as apoptosis and anti-apoptosis, anoikis and cytoskeletal rearrangements, among others, and that distally axotomized MNs survive because these MNs differently engage the anti-anoikis program and selective autophagy (Casas et al., 2015). Although not fully understood, this divergence in the molecular mechanisms between MN degeneration or regeneration may be due to the proximity of the injury to the soma. This provokes a more severe disturbance of the cell organelles after preganglionic injury and a harmful response to stress which leads to the opposite molecular responses (Penas et al., 2011b).

These descriptions were not enough to identify specific targets for a neuroprotective therapeutical strategy. We did not want to implement the reductionist vision -- one drug for one target for one disease -- approach. Instead, we wanted to take advantage of breakthroughs in systems biology and pharmacology approaches as well as in computational tools for big data analysis to design a network-centric-based drug discovery process. Network analysis can be used to elucidate the intricate connections that form the biological systems and how they are disturbed in pathological conditions (Barabási, 2007). The increasing amount of biological data from a variety of 'omics platforms (genomics, transcriptomics, proteomics, and metabolomics) have assisted in the development of various *in silico* approaches that connect molecular data to their biological functions using knowledge bases as templates to build associations between them. Recently developed computational tools allow unique virtual screening strategies for polypharmacology and prediction of adverse and therapeutic polypharmacological effects and supervised machine-learning algorithms that enable prediction of drug-target interactions (Lavecchia, 2015) have revolutionized the workflow for drug discovery. Network models enable analysis of complex interaction networks between drugs and their targets aiding in elucidation of mechanisms of action (Cheng et al., 2012; Woo et al., 2015). Statistical models that make use of a data integration framework have been effectively applied both to predict novel drug indications and to identify potent drug combination strategies (Keiser et al., 2007). Computational/experimental frameworks have also been implemented for the systematic design of multi-targeted drugs (Bottegoni et al., 2012).

In the discovery of NH, we used the technology known as the therapeutic performance mapping system, which allows generation of disease-specific mathematical models for drug screening using neural artificial intelligence-based methods for machine learning (Pujol et al., 2010; Herrando-Grabulosa et al., 2016; Romeo-Guitart et al., 2017, 2018). Therapeutic performance mapping system is based on the building of the molecular networks characteristic of an specific health condition (either normal or pathological) using network and systems biology approaches (Pujol et al., 2010). Therapeutic performance mapping system facilitates the screening of drugs for their capacity to shift the profile of topological molecular maps from pathological to beneficial or normal (Herrando-Grabulosa et al., 2016). For this purpose, maps are converted into mathematical models using artificial artificial neural networks and sampling methods as computational tools, and machine learning allow the screening and choice of thousands of drug combinations with a desirable effect (*e.g.*, neuroprotection) (Badiola et al., 2013). In our work, we sought to identify a combination of clinically used drugs that would be capable of converting the degeneration-associated map that describes the RA condition into the neuroprotective and regenerative-associated map described by the distal axotomy condition. Our therapeutic performance mapping system analysis resulted in a list of putative neuroprotective combinations of US Food and Drug Administration-approved drugs. Thus, computational tools allowed us to focus on the network and to select pharmaceutical combinations putatively capable of boosting endogenous neuroprotective mechanisms. Experimental investigations led us to the combination now known as NH.

We validated that NH increases MN survival after RA, reduces the inflammatory response, protects against endoplasmic reticulum stress *in vitro*, and induces pro-regenerative profiles in MN tracks in spinal cords; the NH components act synergistically (Romeo-Guitart et al., 2018). In addition, we demonstrated that NH treatment accelerates long-term motor function recovery after PNI and root reimplantation (Romeo-Guitart et al., 2017).

It is important to highlight that NH is a combination of two repurposed drugs: acamprosate and ribavirin. Drug repurposing facilitates clinical translation because it drastically reduces the need for preclinical toxicity and efficacy assays and for safety profiling in human volunteers (Ashburn and Thor, 2004). Some successful examples of drug repurposing include a glycogen synthase kinase- 3β-targeted therapy for the treatment of glioblastoma (Furuta et al., 2017) and the promising combination of two anti-diabetic drugs that exert neuroprotection in a mouse model of Alzheimer´s disease and in patients with Parkinson disease (Aviles-Olmos et al., 2013; Hettich et al., 2014).

Neuroheal's Mechanism of Action in Neuroprotection and Nerve Regeneration {#sec1-4}
=========================================================================

As evidenced by the increasing number of publications in the recent years, drug discovery is undergoing a steady paradigm shift from the ideology of selective agents ('magic bullets') toward selectively promiscuous multi-targeting drugs ('magic shotguns') (Roth et al., 2004; Strebhardt and Ullrich, 2008). The polypharmacology-based "one drug, multiple targets" paradigm has benefits relative to the conventional *de novo* approaches to drug discovery (DiMasi, 2001; Dickson and Gagnon, 2004). In the case of nerve regeneration, multi-targeting gives the opportunity to act through several pathways in parallel to support the neuroprotective and pro-regenerative phenotype. Analysis with computational tools allowed us to identify putative proteins (nodes) that mediate the synergistic mechanism of action of NH. Important nodes belong to the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (AKT) axis and anti-apoptotic pathways (p53, the apoptosis blocker X-linked inhibitor of apoptosis protein, cytoskeletal motor protein kinesin heavy chain isoform 5 (KIF5), and dynactin subunit 1 (DCNT1)), and the Src-integrin axis (the integrin subunit integrin beta-1 and the nicotinamide adenine dinucleotide-dependent deacetylase sirtuin 1 (SIRT1)) (Romeo-Guitart et al., 2018) (**[Figure 1](#F1){ref-type="fig"}**).

![Neuroheal exerts neuroprotective and regenerative effects after peripheral nerve injury.\
Left, String protein network representation of minimal mechanism of action of NeuroHeal. In red are highlighted key nodes experimentally proven to be modulated by neuroheal: an increased activity of nicotinamide adenine dinucleotide-dependent deacetylase sirtuin 1 (SIRT1) and serine/threonine-protein kinase protein kinase B (AKT), and an augmented presence of integrin subunit integrin beta-1 (ITGB1), kinesin-related protein KIF5 and dynactin subunit 1 (DCNT1). Right, pleiotropic effects promoted by neuroheal at different levels: the spinal cord motoneuronal soma (MNs) (blue), astrocytes (yellow), and microglia (green), the motor nerve at the peripheral nerve system (blue line), and the muscle (orange). NMJ: Neuromuscular junctions.](NRR-14-1122-g001){#F1}

We have shown that activation of SIRT1 mediated by NH promotes neuroprotection (Romeo-Guitart et al., 2017, 2018). It has been extensively reported that activation of SIRT1 can exert neuroprotection in different neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer and Huntington diseases and in experimental autoimmune encephalomyelitis induced by pharmacological or genetic activation (Kim et al., 2007; Jiang et al., 2012; Nimmagadda et al., 2013; Watanabe et al., 2014). In the context of trauma, SIRT1 activation reduces functional impairments after spinal cord injury (Chen et al., 2017). Although some reports indicate that SIRT1 activation has beneficial effects and improves functional recovery after traumatic brain injury (Wu et al., 2007), its role after stroke remains controversial (Petegnief and Planas, 2013). Mice that overexpress SIRT1 have ameliorated amyotrophic lateral sclerosis pathophysiology (Watanabe et al., 2014). We found that co-treatment of the RA-injured animals with NH and the selective SIRT1-activity inhibitor Ex-527 blocked NH pro-survival effects (Romeo-Guitart et al., 2017, 2018). Indeed, the overexpression of SIRT1 in spinal MNs using an adeno-associated viral vector increased MN survival after RA. Although SIRT1 activation is essential for NH neuroprotection, SIRT1 activation alone is not responsible for the beneficial spectrum of neuroprotection that NH exerts revealing the importance of its multi-target nature (Romeo-Guitart et al., 2018). Moreover, NH normalized the location or abundance of cytoskeletal motor proteins KIF5C and DCNT1, two transport proteins related with neurodegeneration or axonal disturbances. The kinesin family is formed by the kinesin-1 (historically named kif5c) and the kinesin-3 (KIF1A, KIF1Bα and KIF1Bβ) members (De Vos and Hafezparast, 2017). KIF5C is enriched in MNs (Kanai et al., 2000) and its genetic ablation or spontaneous mutation are linked with MN diseases and paralysis (Xia et al., 2003; De Vos and Hafezparast, 2017). Besides, a dysfunctional dynein/DCTN1 has been used as an ALS mice model. Its mutation causes a defective axonal transport that leads to an amyotrophic lateral sclerosis-like phenotype in mice and to MN degeneration (LaMonte et al., 2002; Heiman-Patterson et al., 2015). Finally, the increase on β-1 integrin can be yielding anti-anoikis effects to the MNs. In fact, the concomitant activation of AKT axis with an increase of β-1 integrin may be inhibiting anoikis in our model (Bouchard et al., 2007).

Although maintenance of MNs can be achieved after RA experimentally by different pharmacological treatments, translation to the human healthcare has never been performed. For example, the Pre084 compound, an agonist of the sigma receptor 1, is a good neuroprotectant but use systemically causes neuropathic pain, precluding clinical application (Penas et al., 2011b; Roh et al., 2011; Pyun et al., 2014). Other compounds such as N-acetyl-cysteine, GM-1 ganglioside, and valproic acid maintain MN pool, but their ability to enhance nerve regeneration has not been reported (Oliveira and Langone, 2000; Zhang et al., 2005; Wu et al., 2013). Riluzole, lithium, and an inhibitor of the proteoglycan receptor are neuroprotective in a model of RA with the immediate reimplantation of roots (Bergerot et al., 2004; Li et al., 2015; Fang et al., 2016). These compounds promote long-term survival of MN, as does NH, after injury, but in tests of these compounds, reparative surgery was performed immediately after RA, so it is unclear if they also protect MNs after a delayed root reimplantation. We showed that NH sustains MN survival for two weeks after RA in the absence of reparative surgery (Romeo-Guitart et al., 2017).

Although mammalian neurons have intrinsic capabilities to replace and repair axons by regeneration, in the best clinical scenario only 10% of axons regenerate to target organs after nerve transection (Janjic and Gorantla, 2017). The formation of the inhibitory glial scar at the central nervous system-peripheral nervous system transition zone after root injury make more difficult axon regrowth in this case than in distal axotomy (Silver and Miller, 2004; Silver et al., 2014). Different molecular pathways have been reported to mediate axonal regrowth within central nervous system and peripheral nervous system (Tedeschi, 2012). Among them, the PI3K/AKT axis, which is activated by neurotrophic factors, is the best characterized (Caporali et al., 2008). PI3K is very sensitive to PTEN (gene of phosphate and tension homology deleted on chromsome ten), which blocks PI3K and reduces the pro-regenerative effect of the axis (Berry et al., 2016). Several approaches, including *PTEN* deletion (Park et al., 2008) and its pharmacological inhibition, enhance axonal regrowth through the glial scar after injury to the central nervous system (Ohtake et al., 2014). However, the suppression of PTEN activity cannot be translated to the clinic due to its tumour-suppressor role (Tolkacheva and Chan, 2000). Thus, discovering new drug therapies that increase axonal regrowth by AKT activation without affecting PTEN has raised much interest (Tolkacheva and Chan, 2000). We demonstrated that NH reduces glial scar formation and enhances axonal regrowth after distal or proximal injury (Romeo-Guitart et al., 2017, 2018). Acceleration of nerve regeneration resulting from NH treatment is accompanied by an increase in compound muscle action potential at the muscles innervated by the L4--6 MNs. NH probably enhances nerve regeneration because it increases PI3K/AKT axis activity and growth associated protein 43 expression, a pro-regenerative factor also called neuromodulin (Denny, 2006; Holahan, 2017).

Very few drugs that enhance axonal regeneration after PNI have been described in the literature (Al-Majed et al., 2000; Elzinga et al., 2015). These are FK506, geldanamycin, N-acetylcysteine, acetyl-L-carnitine, IGF, chondroitinase ABC, and neurotrophic factors (Navarro et al., 2001; Welin et al., 2009; Sun et al., 2012; Farahpour and Ghayour, 2014; Janjic and Gorantla, 2017). All have undesired side effects such as immunosuppression in the case of FK-506 and tumorigenesis mediated by neurotrophic factors (Tannemaat et al., 2008). Some compounds, including riluzole, lithium, and an inhibitor of the proteoglycan receptor, have been demonstrated to increase axonal regeneration after RA with immediate root reimplantation (Bergerot et al., 2004; Li et al., 2015; Fang et al., 2016). However, in this model is difficult to distinguish whether functional recovery is mediated by an increase in MNs survival or by a specific effect on axonal regeneration. NH, as a combination of two repurposed drugs, has clear advantages in terms of clinical translation.

After traumatic injuries to the nervous system, such as PNI, neurodegenerative diseases, or intensive health-care periods, muscle is considerably atrophied (Powers et al., 2016). Skeletal muscle atrophy is correlated with a high mortality and morbidity risk (Calvani et al., 2013). The importance of muscle in recovery after PNI has recently been acknowledged. Recovery depends on efficient reconnection of axons with neuromuscular junctions (NMJs) from muscle, and this muscle must be minimally atrophied. We have observed that NH treatment reduces muscle-denervated atrophy and increases the number of functional NMJs (**[Figure 1](#F1){ref-type="fig"}**). Hence, NH treatment shows clear positive combined effects on neuroprotection and axonal regeneration, and its activity shows that mimicking endogenous mechanisms can lead to effective therapeutic designs.

Conclusion and Summary {#sec1-5}
======================

An optimal therapeutic strategy after PNI must sustain long-lasting neuronal viability, enhance axonal regrowth, favour functional reinnervation of NMJs, and reduce muscle atrophy. Covering all these aspects by influencing a single target is likely impossible, and, therefore, multi-targeting drugs are desired. The nervous system, like other systems in the body, has the availability to engage endogenous mechanisms in the face of injury that allow neurons to survive, axons to speedily regenerate, and healthy denervated muscle to be sustained. We reasoned that potentiating these mechanisms might result in effective neuroprotection and repair of the damaged nervous system. NH was discovered using a systems biology and neural artificial intelligence-based computational tools in a network-centric vision for drug discovery. In animal models, NH boosts endogenous mechanisms and its multi-targeting nature activates multiple factors necessary for functional recovery after PNI, resulting in neuronal survival, axonal regrowth, and limited denervated muscle atrophy.
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